Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SCIENTURE HOLDINGS INC (SCNX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$3.10-9.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SCNX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Resolution of ongoing litigation without material financial impact | A supporting condition in SCIENTURE HOLDINGS INC's published investment case. The stated target is No material adverse rulings or settlements in next 12 months. | Under Pressure | Material adverse litigation rulings or settlements impacting financials | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story with fragile earnings quality: revenue is growing from a very small base, but the company remains loss-making. The long-term thesis is intact, with recent commercial progress, though management execution is volatile and risk remains elevated.
SCNX carries a durable premium versus peers, about 1.8 times the peer level, while its business is still loss-making. The evidence does not show a broad, high level of fragility already priced in, so the market may not fully reflect the risks from weak execution and unsettled results.
Near-term revenue has risen from $56,325 in Q1 to $343,639 in Q2, with preliminary Q3 revenue of about $1.22 million as Arbli sales grew and REZENOPY launched. Expense cuts also narrowed the Q2 operating loss, but the company remains loss-making and its 2027 profitability goal is still ahead. A possible guidance cut, a weak jobs backdrop, and recent legal and listing events add near-term uncertainty.
Over the next few quarters, the thesis hinges on whether Arbli and REZENOPY adoption continues and revenue growth becomes more durable. It also depends on expense discipline translating into progress toward profitability without a guidance cut. Strong results and guidance from healthcare peers could support sector momentum, while a weakening jobs report could weigh on cyclical healthcare names.
For the 1-to-3-year view, commercial progress supports an intact thesis, but the premium valuation, ongoing losses, and elevated company-specific and economic risks leave execution as the central test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable and effective management team |
| A supporting condition in SCIENTURE HOLDINGS INC's published investment case. The stated target is No further key executive departures in next 12 months. |
| Under Pressure |
| Additional departures of key executives such as CFO or CEO within next 12 months |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful commercialization of Arbli TM and launch of REZENOPY TM | Scienture is advancing its drug pipeline with plans to commercialize Arbli TM and launch REZENOPY TM in 2026. | Improving | Failure to launch or generate meaningful revenue from Arbli TM and REZENOPY TM in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth above minimal guidance | A primary condition in SCIENTURE HOLDINGS INC's published investment case. The stated target is Revenue exceeds $60 million in FY26 and grows toward $17.2 million in FY27. | Broken | Revenue falls below $60 million in FY26 or fails to show growth toward $17.2 million in FY27 | Revenue: $343,639 FY2026-Q2; GAAP. Published target: Revenue exceeds $60 million in FY26 and grows toward $17.2 million in FY27. Target period is not explicitly aligned with this observation. Aug 13, 2026343,639 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.06 → $-0.27 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-25 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-26 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-27 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-28 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-29 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-30 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-07-31 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-01 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-02 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-03 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-04 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-05 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-06 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-08 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-09 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-10 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-12 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-13 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-14 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-15 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-16 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-17 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-18 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-19 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-20 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-21 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-22 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-23 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-24 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-25 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-26 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-27 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-28 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-29 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-30 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-08-31 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-01 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-02 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-03 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-04 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-05 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-06 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-07 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-08 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-09 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-10 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-11 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-12 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-13 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-14 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-15 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-16 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-17 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-18 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-19 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-20 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-21 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-22 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-23 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-24 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-25 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-26 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-27 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-28 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-29 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-09-30 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-01 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-02 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-03 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-04 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-05 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-06 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-07 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-08 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-09 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-10 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-11 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-12 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-13 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-14 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-15 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-16 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-17 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-18 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-19 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-20 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-21 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-22 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-23 | $-0.06 | $17,217,000 | 1 / 1 |
| 2026-10-24 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-25 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-26 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-27 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-28 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-29 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-30 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-10-31 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-11-01 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-11-02 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-11-03 | $-0.27 | $15,471,000 | 1 / 1 |
| 2026-11-04 | $-0.27 | $15,471,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.